Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifupinostat + rituximab
- Development stage
- Unknown
- Lead developer
- BeBetter Med
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ifupinostat + rituximab is an investigational combination therapy for *relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)*. **Ifupinostat (BEBT-908)** is an oral, small molecule *dual HDAC/PI3K inhibitor* developed by BeBetter Med, representing a first-in-class therapy targeting both histone deacetylase and phosphoinositide 3-kinase signaling. **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, approved for various B-cell malignancies. The combination leverages ifupinostat’s epigenetic and PI3K pathway modulation with rituximab’s targeted B-cell depletion, aiming to improve outcomes in lymphoma patients. Clinical trials have demonstrated *efficacy and manageable safety* in second-line treatment of r/r DLBCL, with a reported objective response rate of 76.2% in Phase Ib and ongoing confirmatory Phase III trials[1][2][3][4][6][8].
- Other names
- ifupinostat + rituximab
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)CD20 (B-lymphocyte antigen CD20)HDAC (HDAC family)
Beyond the preview
Go deeper on ifupinostat + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifupinostat + rituximab.